Background and Objective Immunoglobulin replacement therapy (IRT) is often used to support patients with primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID). Home-based subcutaneous immunoglobulin (SCIg) is reported to be a cheaper and more efficient option compared to hospital-based intravenous immunoglobulin (IVIg) for PID. In contrast, there is little information on the cost-effectiveness of IRT in SID. However, patients who develop hypogammaglobulinaemia secondary to other conditions (SID) have different clinical aetiology compared to PID. This study assesses whether SCIg provides a good value-for-money treatment option in patients with secondary immunodeficiency disease (SID).
Introduction
Hypogammaglobulinaemia in primary immunodeficiency disease (PID) is genetic in origin, while in secondary immunodeficiency disease (SID), it is due to other conditions and/or treatment regimes. Hypogammaglobulinaemia places patients at an increased risk of developing infection, which in turn affects their morbidity and mortality. These patients benefit from immunoglobulin replacement therapy (IRT) to manage infection risk and to prevent the development of associated complications, such as bronchiectasis. Unlike PID, the incidence of hypogammaglobulinaemia in SID increases with severity or stage of the underlying malignancy and treatment regimes [1, 2] , and there is an increase in major infections with the progression of underlying disease [3] .
In Australia, the demand for immunoglobulin products has been increasing by 11% each year for the last decade [4] . According to the National Blood Authority report, the introduction of a set of criteria for the clinical use of immunoglobulin and to a lesser extent population growth has contributed to this increase [4] . In 2015/16 the cost of supplying immmunoglublin products reached A$ 541.5 million, which made up almost half of Australia's total blood budget [4] . This treated less than 17 000 people, with SID patients being the highest immunoglobulin user group (22Á2%), followed by patients with chronic inflammatory demyelinating polyneuropathy (21Á5%) and PID (13Á3%) [4] .
For decades, the immunoglobulin product has been administered intravenously (IVIg) at a health service centre by a registered nurse once every 4 weeks. Subcutaneous immunoglobulin (SCIg), which can be self-administered by the patient on a weekly basis at a place convenient to them, became available in Australia in 2013 [5] . Currently, less than 4% of SID patients in Australia are using SCIg [6] , which is comparable to the reported 4Á6% use in Europe [7] . In contrast, approximately 50% of PID patients use SCIg [8] . SCIg has been shown to be a cost-effective treatment option in various PID cohorts [9-11] and a combined cohort of PID and SID patients [12] . The disparity in SCIg uptake combined with the differences in aetiology between PID and SID, led us to question whether SCIg is a cost-effective treatment option in SID patients. To answer that question, we undertook a cost-utility analysis and focused on IRT use in SID patients, specifically on patients with acquired hypogammaglobulinaemia secondary to malignancy or its treatment regimes.
Methods
A Markov cohort simulation model was constructed to compare the hospital-based IVIg and the newer homebased SCIg treatment mode. The difference in clinical pathways, disease progression, costs and health outcomes of the two treatment options was modelled using TreeAge Pro 2017, R2Á1 (TreeAge Software, Williamstown, MA). Probabilistic sensitivity analysis was used to quantify the level of confidence in the output of the analysis in relation to uncertainty in the model inputs (e.g. cost and outcomes). The primary outcomes were cost to the healthcare system and health outcomes, as quantitated in quality-adjusted life years (QALYs). The clinical outcomes modelled were the incidence of infection at home or hospital, development of bronchiectasis (with and without infection), bronchiectasis with chronic Pseudomonas aeruginosa infection and mortality.
The target population was adult patients with SID specifically acquired hypogammaglobulinaemia secondary to malignancy or associated treatment. The cohort included eight females and five males, with a mean age of 62Á5 years (39-76). No patient developed bronchiectasis or died within the 24 months period. Four patients had bronchiectasis at beginning of observation period. Two patients died 2 years post this study observation period. Seven patients were retired, four were employed, and two patients were unemployed at time of data collection.
All 13 patients for whom clinical and cost data were collected were treated at the tertiary Sunshine Coast Hospital and Health Service (SCHHS), which serves a population of approximately 300 000 people. We had ethics approval to administer the AQoL-6D survey to patients at the tertiary Gold Coast University Hospital (GCUH), while they were setting up their SCIg program. This increased the number of survey responses. Both hospitals are in Queensland, Australia.
Model structure
The six health states used were as follows: SID no infection, SID with infection, SID with bronchiectasis no infection, SID with bronchiectasis with infection, SID with bronchiectasis and chronic Pseudomonas aeruginosa infection, and death ( Fig. 1 and Fig. A1 ). The different costs for health care associated with each health state, the quality of life estimate using the Assessment of Quality of Life-6 Dimensions (AoQL-6D) instrument (www.aqol.c om.au) and the probability of remaining or transitioning into another health state were taken into account. The transition probabilities were estimated from our cohort data or from the literature [13] [14] [15] , and from the life table on mortality from all causes by age (www.abs.gov.au/aus stats/abs@.nsf/mf/3302.0.55.001).
As SCIg is administered weekly, a weekly cycle was chosen with a time horizon of 10 years. To assess the distribution of outcomes from the simulations based on ranges in treatment cost, transition probabilities and QALYs, a probabilistic sensitivity analysis with 50 000 iterations was performed. Triangular distributions with variations ranges from 50 to 150% of the mean value were selected to simulate changes in costs. The beta distribution was selected to assess variations in QALYs with observed means and standard deviations. The Dirichlet distribution was selected to account for multinomial probability distributions. 
Data inputs and sources

Probabilities
The mean annual number of infections in our cohort was 1Á85 on IVIg and 2Á31 on SCIg (n = 13), which was not statistically different (Table 1) . We could not find any study that reported a significant difference in the number of infections between treatment options. The rate of hospitalization due to infection in our cohort decreased from 0Á13 on IVIg to 0Á03 on SCIg ( Table 1 ), indicating that while the numbers of infections increased on SCIg, they may have been less severe in our cohort on SCIg.
The infection data from our cohort were used in the model with the exception of transition probabilities for Pseudomonas aeruginosa infection and death. As neither were observed in our cohort over the 52 weeks period, data from the literature were used [13, 15 ]. There appears to be no Australian data available on death caused by Pseudomonas aeruginosa infection. It has been reported that the risk of mortality in SID patients is 2Á55 times higher compared to general population [14] , which was included in the model (Table A1 ).
Costs
The cost of Ig product per gram was obtained from the National Blood Authority (NBA) website in April 2018 (https://www.blood.gov.au/); this cost excludes plasma for fractionation [5] . In Australia, 56% of Ig issued was the domestic product at $ 58Á49/g for both IVIg and SCIg, and 44% was the imported product at $ 45/g for IVIg and $ 57Á43/g for SCIg [6] . The weighted mean cost was used in the model (Table 1) . Our mean cohort product usage was 29Á46 g/month on IVIg and 31Á15 g/ month on SCIg.
A mean of three training sessions was required for patients to reach competency at SCIg self-administration, which accrues a direct and indirect outpatient ward cost of $ 600. Each session lasted approximately 2Á5 h. The cost of consumables (syringes, needles, cannula, infusion lines, alcohol wipes) increased from $ 21Á40/ month on IVIg to $90Á48/month on SCIg, due to the difference in frequency of administration (monthly vs. weekly).
All patients used the Springfusorâ pump (Go Medical Industries Pty Ltd)(A$ 100) to administer SCIg, which can be reused for approximately 100 infusions. In Australia, IRT is provided at no additional direct cost to patient [16] . As these infusion pumps were provided by the health system, this cost was included in the model. The IVIg infusion pumps (A$ 2000) are ward equipment that is used by all patients treated in that ward. The life expectancy of these pumps is estimated at 15 years and assuming it served three patients per day would equate $ 0Á17 per patient treatment. This cost is included in the total ward cost for treatment ( Table 1) .
The mean weekly direct and indirect ward cost for IVIg treatment was $ 53Á54, and this included the use of a treatment chair for infusion and nursing supervision of 4-6 h per infusion. SCIg treatment was $ 24Á08 per week and included approximately 15 min of nursing staff time for review and the product pick up.
Analgesics to treat side-effects such as headaches were excluded, as these are over-the-counter medicines and not a cost to the health service. No serious adverse events requiring hospitalization due to IRT were reported in our cohort.
Pathology tests to screen for infections (bacterial, viral, fungal) and to monitor serum IgG trough levels were included ( Table 1 ). The mean cost of treatment for infection at ED is $ 401Á81 for our cohort data, and $ 54Á38 for treatment by GP. While on IVIg, 38% of infectious episodes resulted in an ED instead of GP visit, and with SCIg 27% led to ED visits. The weighted mean cost was calculated for treatment of infection that did not require hospital admission (Table 1) .
Data were collected over two consecutive years with the IVIg period being first. As the underlying disease may have progressed in this time, the mean length of hospital stay per infectious episode for IVIg and SCIg period combined was used in the model. This was 3Á29 days in patients without bronchiectasis and 5Á50 days in patients with bronchiectasis per infectious episode.
Utility values
The AQoL-6D survey was handed out to each SID patient when they visited the SCHHS or GCUH for IVIg or SCIg treatment or pickup of SCIg product. This was a larger 
Results
The results show SCIg is the dominant strategy compared to IVIg, with greater QALYs at lower cost (Table 3) .
Deterministic sensitivity analysis
A deterministic analysis was conducted by allowing costs, utilities and discount rates to vary arbitrarily from their reported mean. Figure 2 shows that the model is most sensitive to costs without infection, that is product and IRT treatment costs, followed by costs of bronchiectasis. The product cost itself makes up the largest proportion of overall treatment cost. Our sensitivity analysis showed that numbers of infections had no impact on outcome of model. The increase in infections of 83Á4% from base case was defined as the threshold where SCIg is less effective than IVIg, but remained cheaper. Compagno's study [19] appears to be the only one comparing infection rate between IVIg and SCIg in SID patients and they reported no significant difference. This indicates similar probabilities of infection between treatment modes, while the cost associated for treatment of infection may vary between states and countries. However, variation in probability of infection had little effect on the model.
Probabilistic sensitivity analysis
The SCIg treatment mode incurs a mean lower cost and overall higher QALYs compared to IVIg, including at the lower and upper bound 95% confidence interval.
The Monte Carlo simulation indicates that 88Á4% of simulations lie below the WTP line (Fig. 3) . While 61Á8% of those simulations had lower cost and higher QALYs, 26Á6% had higher cost and higher QALYs but with an ICER <A$ 50 000. The SCIg mode was not cost-effective in 11Á7% of iterations (higher cost and lower QALYs), with an ICER greater than A$ 50 000 per QALY.
Discussion
This is the first cost-utility analysis conducted to examine the cost-effectiveness of the home-based SCIg treatment option compared to the hospital-based IVIg in SID patients in Australia. The results of this analysis show that SCIg is a cost-effective treatment option for SID patients in Queensland (Australia), with mean cost savings over a 10-year period of A$ 8082 with SCIg. Based on the data from this small observational study, SCIg appears to be the preferred administration mode.
The mean age of our cohort was 63 years, similar to the 56-64 years reported in the literature [20] [21] [22] . It has been estimated that 52-62% of chronic lymphocytic leukaemia (CLL) patients have hypogammaglobulinaemia at diagnosis [1, 23] , with 17-27Á3% having IgG deficiency [23, 24] . Interestingly, hypogammaglobulinaemia at diagnosis has been reported with an increased all-cause mortality risk [23] , which suggest that it may be a marker of aggressiveness of cancer and progression of disease [1, 2, 23] . This distinguishes SID patients from PID patients. However, current SCIg guidelines for SID patients heavily rely on PID experience, including health economic analysis. Only a combined PID and SID model was found, which estimated SCIg being cost-effective for the healthcare sector [12] . Interestingly, the cost savings in our SID cohort are smaller compared to patients with PID using SCIg at the same hospital (data not shown). In our cohort, SCIg was cost-effective despite the higher cost per gram with the SCIg product and the slightly higher mean SCIg dosage (31Á15 g/month) compared to IVIg (29Á46 g/month). It also resulted in an increase of serum IgG levels from 7Á1 g/l on IVIg to 8Á4 g/l on SCIg. However, despite this increase in IgG levels, the mean infection rate increased from 1Á85 on IVIg to 2Á31 on SCIg. In contrast, one study reported an annual infection rate per patient as 2Á29 on IVIg (n = 33) and 1Á76 on SCIg (n = 61) [19] . A recent study of 231 SID patients reported an annual infection rate of 2Á23, but did not distinguish between treatment mode [25] . Reports on IgG deficiency and the risk of developing infection in SID Fig. 2 Deterministic sensitivity analysis: The triangular distribution was used for all cost variables and a beta distribution for utility variables. Cost and utility values were derived from our cohort data (for details see Table A2 ). (Black bars = use of low parameter value; grey bars = use of high parameter value). ICER, incremental cost-effectiveness ratio; IVIg, Intravenous immunoglobulin; SCIg, subcutaneous immunoglobulin. patients are contradictory. Some studies report no association with infection [1, 23] . Another study reported low serum IgG levels as a risk factor for developing infections in SID patients (P = 0Á011), with an increase in number of infections with the progression of disease [24] .
Secondary immunodeficiency disease patients are heterogeneous because of their different comorbidities, such as diabetes mellitus (12%), thyroid disease (12%) and chronic obstructive pulmonary disease (7%) [7] . In addition, SID patients are often concurrently treated for their underlying condition, relapsing, refractory or have received a haematopoietic stem-cell transplant [25] . The heterogeneity of this cohort may explain why our infection rate is different to Compagno's study [19] . Although the infection cost is high, its contribution to the overall cost is insubstantial as the chance of developing an infection that requires hospitalization is relatively small, even though it varies depending on the stage of underlying disease [2, 24] . Our results show that even with an increase in cost due to infection by 300%, SCIg is still cost-effective.
Studies reported that while IRT resulted in a decrease in number of infections, this did not change overall survival [25, 26] . Death due to cancer has been reported at 64Á8% and is estimated to be 2Á5 higher compared to general population [14] . Risk of mortality in patients with bronchiectasis was reported as 2Á2 times higher compared to general population [15] . However, despite unchanged mortality risk with IRT, patients reported via our project specific questionnaire that they experienced an improved quality of life and less side-effects with IRT (data not shown).
Conclusion
From a healthcare system perspective, SCIg is a costeffective treatment option compared to IVIg for SID patients in Queensland, Australia. Switching SID patients from IVIg to SCIg would result in cost savings to the healthcare sector, as well as improve the quality of life for the patient. Thus, based on this study, the development of an implementation strategy with an evaluation to shift SID patients from IVIg to SCIg is recommended. (1 = SID no infection; 2 = SID with infection; 3 = SID with bronchiectasis no infection; 4 = SID with bronchiectasis with infection; 5 = Bronchiectasis with chronic Pseudomonas aeruginosa infection; 6 = death). 
